Revenue for the three months ended March 31st, 2019, was
$13.3 million, up 132%
Gross margin for the quarter ended March 31st, 2019, was 69%
Net loss for the quarter was $0.2 million or $0.01 per share, compared
to a loss of $0.4 million or $0.02 per share last year
Conference call scheduled for Wednesday May 29th, 2019
MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 28, 2019--
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV;
OTCQX:CVALF), an advanced medical technologies company, today announced
its second quarter fiscal 2019 results.
Brian Pedlar, Covalon’s President and CEO, said, “Our second quarter
financial performance is on track in executing on our fiscal 2019 plan.
Revenue is more than double last year’s second quarter, with growth of
132% and business in the United States accounting for 60% of our revenue
in the first half of the year. I am very pleased that Covalon is
achieving its strategic objective of increasing our North American
business and diversifying away from the Middle East. Combined revenue in
the United States is on track to exceed $25 million in fiscal 2019.
Sales of the recently acquired AquaGuard product line are growing
according to plan and our United States sales force has been engaged in
the process of educating our new customer base of 1,500 hospitals on
Covalon’s infection prevention products. During the quarter, there were
several unplanned items that impacted our overall profitability and a
main focus going forward is growing profits in line with our revenue
“During Q2, we continued our deliveries to schedule on the Middle East
competitive contracts that we previously announced. We expect deliveries
to be more heavily weighted to our fourth quarter ending September 30,
2019, for the remainder of this fiscal year.”
Q2 Fiscal 2019 Financial Results
Revenue for the three
months ended March 31, 2019, increased 132% to $13,312,543 compared to
$5,727,275 for the same period of the prior year. Gross margin for the
three-month period ended March 31, 2019, was 69% compared to 76% for the
same period of the prior year. Net loss for the three months ended March
31, 2019, was $232,227 or $0.01 per share, compared to a net loss of
$479,082 or $0.02 per share for the three months ended March 31, 2018.
Revenue for the six months ended March 31, 2019, increased 70% to
$20,574,029, compared to $12,131,980 for the same period of the prior
year. Gross margin for the six-month period ended March 31, 2019, was
67%, compared to 73% for the same period of the prior year. Net loss for
the six months ended March 31, 2019, was $2,141,638 or $0.10 per share,
compared to a net income of $44,263 or $0.00 per share for the six
months ended March 31, 2018.
Conference Call Scheduled
A conference call to discuss
Covalon’s Q2 Fiscal 2019 Financial Results will be held Wednesday May 29th,
2019, at 9:00am EDT. To participate in the call, please dial:
ID Code: 1599884
A recording of the call will be available by calling 855.859.2056 or
404.537.3406 and entering the conference ID code 1599884 from May 29th,
2019, at 12:00pm EDT to June 12th, 2019, at 11:59pm EDT.
Copies of Covalon’s financial statements and MD&A can be obtained on
SEDAR at www.sedar.com,
as well as the Investor Relations tab of the Company’s website at www.covalon.com.
Covalon Technologies Ltd. researches,
develops, and commercializes new healthcare technologies that help save
lives around the world. Covalon's patented technologies, products, and
services address the advanced healthcare needs of medical device
companies, healthcare providers, and individual consumers. Covalon's
technologies are used to prevent, detect, and manage medical conditions
in specialty areas such as infection control, vascular access, surgical
procedures, advanced wound care, and medical device coatings. To learn
more about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect
the Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will", "should",
"could" or "might" occur or be achieved and other similar expressions.
These forward-looking statements involve risk and uncertainties,
including completion of integration of the AquaGuard acquisition, the
difficulty in predicting product approvals, acceptance of and demands
for new products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or achievements to
differ materially from the results discussed or implied in the
forward-looking statements. Many risks are inherent in the industry;
others are more specific to the Company. Investors should consult the
Company's ongoing quarterly filings for additional information on risks
and uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter any
forward-looking statements whether as a result of new information,
further events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005816/en/
Source: Covalon Technologies Ltd.
Brian Pedlar, CEO, Covalon Technologies Ltd.
905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com